ORGANIZATION
Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
Isao Teshirogi, president of the Japan Pharmaceutical Manufacturers Association (JPMA) and president of Shionogi & Co, commented on the government’s efforts to promote the use of regulatory science (RS) and expressed concerns about Japan’s ability to discover novel drugs in…
To read the full story
ORGANIZATION
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





